- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01894789
Ticagrelor vs Clopidogrel Effect on MFR in CAD Population (PATH)
ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow (MBF) and Reserve (MBFR) Measured With Positron Emission TomograpHy (PET) in Patients With Coronary Artery Disease (CAD): The PATH Study
Ticagrelor is one of 3 anti-platelet medications used in patients with acute coronary syndrome (ACS) to prevent further clot formation and further ischemic damage to myocardial tissue. Overall benefits of one drug over the other is neutral in this generally unstable population. In pre-clinical trials, ticagrelor showed secondary effects, involving the release of adenosine to heart muscle where the demand for blood was increased due to a stress condition. Blood flow was increased, potentially preventing potential damage.
This study will compare ticagrelor, currently only approved for use in ACS patients, against clopidogrel by measuring the myocardial blood flow(MBF) during stress to validate this phenomenon. The effect on blood flow will be measurable by using two specific doses of adenosine as the pharmacologic stress and correlating with measurements of blood flow using positron emission tomography (PET) nuclear imaging.
This study hypothesizes that the increase in MBF during intermediate dose adenosine infusion will be greater in ticagrelor treated subjects compared to clopidogrel treated subjects
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1Y 4W7
- University of Ottawa Heart Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years old
- Stable coronary artery disease on stable medical treatment.
- BMI equal to or less than 30 kg/m2
- No clinically significant abnormalities in baseline laboratory work
- No clinically significant arrhythmias on baseline 12-lead electrocardiogram
- Female subjects must be post-menopausal, surgically sterilized or have negative urine beta human chorionic gonadotropin pregnancy test at initial screening and maintain effective contraceptive methods throughout the trial and for 7 days following the end of dosing treatment.
Exclusion Criteria:
- Any contraindication against the use of clopidogrel, ticagrelor and/or ASA.
- Oral anticoagulation therapy.
- History of intracranial bleeding.
- Recent or active pathological bleeding, such as peptic ulcer.
- Moderate or severe hepatic impairment.
- History or risk of bradycardia.
- Known second- or third-degree AV block without pacemaker
- Dyspnea (NYHA III/IV), wheezing asthma or COPD.
- Coronary artery bypass graft (CABG) surgery within 90 days prior to screening or at any time after consent.
- Percutaneous coronary intervention (PCI) within 90 days prior to screening or at any time following consent.
- Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent.
- Any scheduled surgery during the trial period, including dental.
- Concomitant therapy with strong cytochrome CYP 3A inhibitor or inducer.
- Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)
- Known hypersensitivity to the investigational drug or any of its components.
- Known hypersensitivity to adenosine.
- Lactose intolerance
- Breastfeeding or pregnancy.
- Claustrophobia or inability to lie still in a supine position
- Unwillingness to provide informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: stable CAD management
Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
|
Blinded administration of ticagrelor for 10 days
Otros nombres:
Blinded administration of clopidogrel and placebo for 10 days
|
Comparador activo: CAD comparison group
Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
|
Blinded administration of ticagrelor for 10 days
Otros nombres:
Blinded administration of clopidogrel and placebo for 10 days
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Differences in rest MBF, stress MBF and MBFR between ticagrelor and clopidogrel treated patients as measured by PET
Periodo de tiempo: q 2 weeks blood flow measurements
|
Blinded study drug will be administered for 10 days after which the subject will undergo MPI imaging to measure MBF. The crossover to the other study arm will occur and the study procedure repeated. Actual study drug effect will not be known until the study has completed and the treatment unblinded. |
q 2 weeks blood flow measurements
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
The effect of ticagrelor on rest MBF, stress MBF and MBFR will be compared in the normal versus abnormal segments on a segmental and patient basis in the ticagrelor treated subjects
Periodo de tiempo: q 2 weeks blood flow measurements
|
Blinded study drug will be administered for 10 days after which the subject will undergo MPI imaging to measure rest/stress MBF and myocardial blood flow reserve. The crossover to the other study arm will occur and the study procedure repeated. Actual study drug effecting flow will not be known until the study has completed and the treatment unblinded. |
q 2 weeks blood flow measurements
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Terrence Ruddy, MD, Ottawa Heart Institute Research Corporation
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades cardíacas
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Enfermedad de la arteria coronaria
- Isquemia miocardica
- Enfermedad coronaria
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Inhibidores de la agregación plaquetaria
- Antagonistas del receptor P2Y purinérgico
- Antagonistas del receptor P2 purinérgico
- Antagonistas purinérgicos
- Agentes Purinérgicos
- Ticagrelor
- Clopidogrel
Otros números de identificación del estudio
- 20130105-01H
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Ticagrelor
-
University of FloridaTerminado
-
Collegium Medicum w BydgoszczyTerminado
-
AstraZenecaParexelTerminadoAnemia drepanocíticaAlemania
-
AstraZenecaTerminadoInfarto de miocardio | Carrera | Aterotrombosis | Muerte cardiovascularSuecia, Estados Unidos, Australia, Brasil, Bulgaria, República Checa, Francia, Italia, Corea, república de, Perú, Polonia, Federación Rusa, Sudáfrica, España, Pavo, Reino Unido, Alemania, Filipinas, Porcelana, Hungría, Rumania, Ucrania, Países Bajos y más
-
University of FloridaAstraZenecaTerminadoEnfermedad de la arteria coronariaEstados Unidos
-
Federico II UniversityAdvicePharma GroupTerminadoInfarto de miocardio | Enfermedad de la arteria coronaria | El síndrome coronario agudo | STEMI | IAMSESTItalia
-
Centro Hospitalario La ConcepcionReclutamiento
-
Sheba Medical CenterTerminadoInfarto de miocardio con elevación del ST | Síndromes coronarios agudosIsrael
-
University of KarachiPharmEvo Private Limited., PakistanTerminado
-
Cairo UniversityTerminadoEnfermedades cardiovasculares | El síndrome coronario agudoEgipto